2024
Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
Le G, Wong S, Badulescu S, Au H, Di Vincenzo J, Gill H, Phan L, Rhee T, Ho R, Teopiz K, Kwan A, Rosenblat J, Mansur R, McIntyre R. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal Of Affective Disorders 2024, 355: 342-354. PMID: 38570038, DOI: 10.1016/j.jad.2024.03.165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionLysergic acid diethylamideSerotonergic psychedelicsDepressive disorderHealthy controlsTheta powerHealthy volunteersBiomarkers predictive of responseGamma-band powerAssociated with increased theta powerSystematic reviewDissociative classDose of treatmentPredictive of responseClasses of agentsMood disordersBeta and delta bandsMDDAcid diethylamideMechanism of actionBiomarkers PredictiveDepressionPatient populationModel of network connectivityResearch vistas
2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Kantoff P, Oh W. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet Oncology 2012, 13: 1105-1113. PMID: 23059047, DOI: 10.1016/s1470-2045(12)70263-2.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerProstate cancerSix-gene modelMedian survivalMemorial Sloan-Kettering Cancer CenterSix-geneDana-Farber Cancer InstitutePredictive of survivalSignificantly higher areaLow-risk groupHigh-risk groupBiomarkers predictive of survivalProstate cancer-related genesCancer-related genesPeripheral bloodClinicopathological modelPrognostic informationPrognostic utilityTreatment regimensBiomarkers PredictiveProspective studyDana-FarberIndependent cohortPrognostic biomarkerRisk groupsA validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer.
Oh W, Kantoff P, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Galsky M, Ross R. A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. Journal Of Clinical Oncology 2012, 30: 4516-4516. DOI: 10.1200/jco.2012.30.15_suppl.4516.Peer-Reviewed Original ResearchCastration resistant prostate cancerProstate cancerCastration resistant prostate cancer diagnosisCastration resistant prostate cancer patientsCastration-resistant prostate cancerImmune-based therapeutic strategiesRisk menResistant prostate cancerTime of blood drawPredictive of survivalLow-risk menHigh-risk menTranscriptional profiling of whole bloodBiomarkers predictive of survivalProstate cancer-related genesCohort of menCancer-related genesPredictive biomarkersPeripheral bloodPrognostic informationTreatment regimensBiomarkers PredictivePolymerase chain reactionPatient stratificationClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply